IMAX remains on Wedbush Best Ideas List ahead of Q4 earnings

Wedbush reiterated an Outperform on IMAX with a $46 price target ahead of Q4 results, citing market-share gains, a stronger filmed-for-IMAX slate and operating-leverage potential that could push adjusted EBITDA margins above 50% by 2028. The firm raised its Q4 revenue forecast to $121M (from $118M) and lifted adjusted EBITDA to $47M (Wedbush including non-controlling interests: $53M) while keeping EPS at $0.43 (consensus $0.46). Q4 global IMAX box office came in at $336M (vs Wedbush prior $307M), driven by China ($100M vs $71M) and international ex-China ($124M vs $91M), although domestic was $112M (vs $145M). Wedbush highlighted guidance of ~12% y/y box office growth to ~$1.4B in 2026 and system installations rising ~8% to 160–175 units, supporting a bullish view into the company’s earnings release on Feb. 25.

Analysis

Market structure: IMAX (IMAX) is a clear winner — premium pricing and an expanding installed base (guidance: +~8% to 160–175 units in 2026) increase box‑office share (Q4: >5% NA, ~6% China, >4% Intl) and lift pricing power versus commodity screens. Losers include smaller, non‑premium exhibitors and streaming window economics that compress theatrical exclusivity; studios that fail to deliver filmed‑for‑IMAX (FFI) content risk losing negotiating leverage. Cross‑asset: stronger EBITDA trajectory should mildly tighten credit spreads for high‑beta media names, depress idiosyncratic put demand (lower IV for IMAX), and have negligible direct commodity or FX impact unless China macro weakens demand materially.

Risk assessment: Near term (days) expect post‑earnings volatility around Feb 25 driven by box office vs. guidance; short term (weeks–months) outcome hinges on 2026 slate execution and China box office stability; long term (2026–2028) the 50% adjusted EBITDA target is achievable only if FFI growth, footprint expansion and operating leverage all deliver. Tail risks: China regulatory shocks, a studio content pullback, tech substitution (at‑home premium screens), or a global box office drop >20% that would reverse margins. Hidden dependency: revenue mix and minority‑interest accounting materially alter reported EBITDA — watch consolidated vs. non‑controlling figures.

Trade implications: Direct play — establish a 2–3% notional long position in IMAX, scaling in between $33–$37, target $46 in 12–18 months and use a 15% stop; alternative options — buy a Jan 2027 IMAX 40/55 call spread (debit) sized to equal 1–2% notional to cap downside while retaining upside. Pair trade — long IMAX vs. short Cinemark (CNK) or a small‑cap exhibitor ETF (size 1–2%) to capture premium vs. commodity screen divergence. If IV spikes post‑earnings, sell front‑month calls against longs or implement a calendar spread to collect premium.

Contrarian angles: Consensus may underweight concentration and execution risk — IMAX’s China exposure (high box office from ~1% screens) creates asymmetric downside if China box office falls >15–20% year/year. The market may have fully priced Wedbush’s “trifecta” given ~40% YTD move; if Q4 EPS or 2026 box office guidance misses (revenue < $1.3bn global IMAX box office guide or installs <155), expect a 20–30% downside repricing. Historical analog: premium format cycles (early 2010s) showed rapid reversion when studios withheld FFI; monitor studio release cadence and announced FFI counts as 30–90 day leading indicators.

Key Decisions for Investors

• Establish a 2–3% long position in IMAX (IMAX) on weakness between $33–$37, target $46 within 12–18 months, and set a hard stop at 15% below entry; size to portfolio risk tolerance.
• Buy a Jan 2027 IMAX 40/55 call spread (debit) equal to 1%–2% notional to express bullish view with capped downside; roll or close if IMAX > $55 or implied vol drops >40% from post‑earnings levels.
• Implement a relative‑value pair: long IMAX (1–2% notional) and short Cinemark (CNK) equal dollar notional (1–2%) to capture premium-format outperformance; rebalance if spread widens/closes by 25% or after two quarters of diverging box‑office metrics.
• If IV rises >30% post‑earnings, sell 30–45 day covered calls to harvest premium (strike ~5–10% OTM) against existing long IMAX positions; unwind if short calls are assigned or if guidance upgrades push price above strike by >10%.
• Sell/avoid entry if IMAX reports 2026 global IMAX box office guidance < $1.3bn or system install guidance <155 units, or if China box office guidance implies >15% year‑over‑year downside — these are triggers to cut exposure immediately.